MeiraGTx Holdings MGTX
NASDAQ MGTX
$13.89 -0.08 (-0.57%)
As of: Sep 4, 2026 · 3:59 PM EDT

MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2026)

MeiraGTx Holdings' (MGTX) quarterly Net Income towards Common Stockholders came in at $15.1 million in Q4 2025, up 138.3% YoY from $6.3 million in Q4 2024, and up 129.87% on a QoQ basis from -$50.5 million in Q3 2025.

Analysis

MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

MeiraGTx Holdings (MGTX) has 9 years of Net Income towards Common Stockholders data on file, last reported at $15.1 million in Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 138.3% year-over-year to $15.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$114.2 million (up 22.73% YoY) and the FY2025 annual result came in at -$114.2 million, up 22.73% from the prior year.
  • Net Income towards Common Stockholders climbed to $15.1 million in Q4 2025, from -$50.5 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $20.2 million in Q4 2023 to a low of -$50.5 million in Q3 2025.
  • A 5-year average of -$27.8 million and a median of -$30.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 303.37% — and 2023, when it jumped 174.01%.
  • Tracing MGTX's Net Income towards Common Stockholders over 5 years: stood at -$9.9 million in 2021, then plunged by 175.55% to -$27.3 million in 2022, then jumped by 174.01% to $20.2 million in 2023, then slumped by 294.9% to -$39.4 million in 2024, then surged by 138.3% to $15.1 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at $15.1 million (Q4 2025), -$50.5 million (Q3 2025), and -$38.8 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 MeiraGTx Holdings 1.27 Bn 1.13 Bn 315.67 Mn 239.26 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 239.26 Mn
Dec 31, 2025 15.09 Mn
Sep 30, 2025 -50.51 Mn
Jun 30, 2025 -38.80 Mn
Mar 31, 2025 -39.98 Mn
Dec 31, 2024 -39.40 Mn
Sep 30, 2024 -39.33 Mn
Jun 30, 2024 -48.62 Mn
Mar 31, 2024 -20.44 Mn
Dec 31, 2023 20.22 Mn
Sep 30, 2023 -44.30 Mn
Jun 30, 2023 -29.58 Mn
Mar 31, 2023 -30.36 Mn
Dec 31, 2022 -27.31 Mn
Sep 30, 2022 -37.28 Mn
Jun 30, 2022 -33.97 Mn
Mar 31, 2022 -31.05 Mn
Dec 31, 2021 -9.91 Mn
Sep 30, 2021 -25.95 Mn
Jun 30, 2021 -20.09 Mn